Twist Bioscience Corp — Director's Dealing 2018

Nov 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2018-11-02

Reporting Person: CRANDELL KEITH (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-02	Common Stock	C	1182645	—	Acquired	1182645	Indirect
2018-11-02	Common Stock	C	718275	—	Acquired	1900920	Indirect
2018-11-02	Common Stock	C	266776	—	Acquired	2167696	Indirect
2018-11-02	Common Stock	C	224726	—	Acquired	2392422	Indirect
2018-11-02	Common Stock	P	15000	$14.00	Acquired	2407422	Indirect
2018-11-02	Common Stock	C	894146	—	Acquired	894146	Indirect
2018-11-02	Common Stock	P	60000	$14.00	Acquired	954146	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-02	Series A Preferred Stock	$	C	1182645	Disposed		Common Stock (1182645)	Indirect
2018-11-02	Series B Preferred Stock	$	C	718275	Disposed		Common Stock (718275)	Indirect
2018-11-02	Series C Preferred Stock	$	C	266776	Disposed		Common Stock (266776)	Indirect
2018-11-02	Series D Preferred Stock	$	C	224726	Disposed		Common Stock (224726)	Indirect
2018-11-02	Series D Preferred Stock	$	C	894146	Disposed		Common Stock (894146)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	0	Direct

Footnotes

F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.

F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: Reflects shares purchased in the Issuer's initial public offering.

F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F6: The expiration date is not relevant to the conversion of these securities.